Birgitta L.
- Country
- Sweden
- Department
- Sunderby sjukhus, Sjukhusvagen 10, 971 80 Lulea, Department of Hematology
Research Overview
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Evaluation of Minimal Residual Disease in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients Treated with Ixazomib, Lenalidomide, and Dexamethasone
- Evaluation of Acalabrutinib Monotherapy in Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase 3b, Multicenter, Open-Label Study
Data & Insights
Has run more than one trial at 27 of 164 partner sites.
Specializations
Hematologic Malignancies
Clinical work centers on chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma, and acute myeloid leukemia, with interest in both newly diagnosed and relapsed or refractory disease. The portfolio also includes chronic myeloid leukemia and precursor states such as smoldering multiple myeloma.
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Multiple myeloma
- Acute myeloid leukemia
Therapeutic interests include targeted agents, immunotherapy, and transplant-related treatment strategies in blood cancers.
Solid Tumors and Precision Oncology
Research activity extends to non-small cell lung cancer, including advanced non-small cell lung cancer with HER2 mutation, and colorectal cancer with molecular alterations in the PI3K signaling pathway. The investigator is also involved in studies of cervical cancer prevention and HPV-related disease.
- Non-small cell lung cancer
- Colorectal cancer with PIK3CA-related alterations
- HPV infection and cervical neoplasia
- HER2-mutated lung cancer
The therapeutic focus includes biomarker-defined oncology, adjuvant treatment strategies, and prevention-oriented cancer care.
Cardiovascular and Metabolic Disease
Clinical interests include atrial fibrillation in the setting of chronic kidney disease stage 5, dyslipidemia, and type 2 diabetes. The investigator is also engaged in cardiovascular risk reduction after acute myocardial infarction.
- Atrial fibrillation with advanced kidney disease
- Dyslipidemia
- Type 2 diabetes
- Post-myocardial infarction prevention
These activities reflect interest in anticoagulation, lipid lowering, and metabolic disease management in high-risk patient groups.
Infectious and Antimicrobial Care
Work in this area includes urinary tract infection and bacteremia caused by extended spectrum beta-lactamase-producing Enterobacterales, as well as acute tonsillitis and HPV infection. The portfolio also touches on infection prevention and antibiotic-sparing care pathways.
- Multidrug-resistant urinary tract infection
- Acute tonsillitis
- HPV-related disease
- Antimicrobial stewardship
The therapeutic emphasis lies in refining treatment options for resistant infections and common community-based infectious conditions.
Perioperative and Obstetric Care
Additional clinical involvement covers induction of labour, surgery under general anesthesia, and post-operative nausea and vomiting, with attention to recovery and symptom control in procedural settings.
- Outpatient labour induction
- General anesthesia
- Post-operative nausea and vomiting
- Perioperative recovery
This area includes maternal care and perioperative supportive treatment aimed at improving procedural tolerance and postoperative recovery.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.